Apogee Therapeutics to Participate at the Stifel 2024 Immunology and Inflammation Summit
Apogee Therapeutics (Nasdaq: APGE), a clinical-stage biotechnology company, has announced its participation in the Stifel 2024 Immunology and Inflammation Summit. The company's management will engage in a fireside chat on September 18, 2024, at 12:30 p.m. E.T. / 9:30 a.m. P.T.
Apogee specializes in developing novel biologics for major inflammatory and immunology (I&I) markets, focusing on treatments for atopic dermatitis, asthma, chronic obstructive pulmonary disease (COPD), and other I&I indications. Their approach aims to offer potentially differentiated efficacy and dosing options.
Interested parties can access a live and archived webcast of the presentation through the News & Events page in the Investors section of Apogee Therapeutics' website.
Apogee Therapeutics (Nasdaq: APGE), un'azienda biotecnologica in fase clinica, ha annunciato la sua partecipazione al Stifel 2024 Immunology and Inflammation Summit. La direzione dell'azienda prenderà parte a una chiacchierata informale il 18 settembre 2024, alle 12:30 E.T. / 9:30 P.T.
Apogee si specializza nello sviluppo di nuovi biologici per i principali mercati di infiammazione e immunologia (I&I), concentrandosi sui trattamenti per dermatite atopica, asma, bradicardia cronica ostruttiva (BPCO) e altre indicazioni I&I. Il loro approccio mira a offrire potenzialmente un'efficacia differenziata e opzioni di dosaggio.
Le parti interessate possono accedere a una trasmissione in diretta e registrata della presentazione attraverso la pagina News & Events nella sezione Investitori del sito web di Apogee Therapeutics.
Apogee Therapeutics (Nasdaq: APGE), una empresa biotecnológica en etapa clínica, ha anunciado su participación en el Stifel 2024 Immunology and Inflammation Summit. La dirección de la empresa llevará a cabo una charla informal el 18 de septiembre de 2024, a las 12:30 p.m. E.T. / 9:30 a.m. P.T.
Apogee se especializa en desarrollar nuevos biológicos para los principales mercados de inflamación e inmunología (I&I), centrándose en tratamientos para dermatitis atópica, asma, enfermedad pulmonar obstructiva crónica (EPOC) y otras indicaciones de I&I. Su enfoque busca ofrecer potencialmente una eficacia diferenciada y opciones de dosificación.
Las partes interesadas pueden acceder a una transmisión en vivo y grabada de la presentación a través de la página de Noticias y Eventos en la sección de Inversores del sitio web de Apogee Therapeutics.
아포지 테라퓨틱스(Apogee Therapeutics) (Nasdaq: APGE), 임상단계에 있는 생명공학 회사가 Stifel 2024 Immunology and Inflammation Summit에 참여한다고 발표했습니다. 회사 경영진은 2024년 9월 18일, 오후 12:30 E.T. / 오전 9:30 P.T.에 화상 대담에 참여할 예정입니다.
아포지는 중증 염증 및 면역학(I&I) 시장을 위한 새로운 생물학적 제제를 개발하는 데 전문화되어 있으며, 아토피성 피부염, 천식, 만성 폐쇄성 폐질환(COPD), 및 기타 I&I 적응증에 대한 치료법에 주력하고 있습니다. 그들의 접근 방식은 우수한 효과와 용량 옵션을 제공하는 것을 목표로 합니다.
관심 있는 분들은 아포지 테라퓨틱스 웹사이트의 투자자 섹션 내 뉴스 & 이벤트 페이지를 통해 발표의 실시간 및 녹화된 웹캐스트에 접속할 수 있습니다.
Apogee Therapeutics (Nasdaq: APGE), une entreprise de biotechnologie en phase clinique, a annoncé sa participation au Stifel 2024 Immunology and Inflammation Summit. La direction de l'entreprise participera à une discussion informelle le 18 septembre 2024, à 12h30 E.T. / 9h30 P.T.
Apogee se spécialise dans le développement de nouveaux biologiques pour des marchés majeurs d'inflammation et d'immunologie (I&I), en se concentrant sur les traitements pour dermatite atopique, asthme, maladie pulmonaire obstructive chronique (BPCO) et d'autres indications I&I. Leur approche vise à offrir potentiellement une efficacité différenciée et des options de dosage.
Les parties intéressées peuvent accéder à une diffusion en direct et enregistrée de la présentation via la page News & Events dans la section Investisseurs du site Web d'Apogee Therapeutics.
Apogee Therapeutics (Nasdaq: APGE), ein biopharmazeutisches Unternehmen in der klinischen Phase, hat seine Teilnahme am Stifel 2024 Immunology and Inflammation Summit bekannt gegeben. Das Management des Unternehmens wird am 18. September 2024 um 12:30 Uhr E.T. / 9:30 Uhr P.T. an einem Fireside-Chat teilnehmen.
Apogee ist auf die Entwicklung neuer Biologika für wesentliche Märkte in der Entzündungs- und Immunologie (I&I) spezialisiert und konzentriert sich auf Behandlungen für atopische Dermatitis, Asthma, chronisch-obstruktive Lungenerkrankung (COPD) und andere I&I-Indikationen. Ihr Ansatz zielt darauf ab, potenziell differenzierte Wirksamkeit und Dosierungsoptionen anzubieten.
Interessierte Parteien können über die News & Events-Seite im Investorenbereich der Website von Apogee Therapeutics auf eine Live- und aufgezeichnete Webcast-Präsentation zugreifen.
- None.
- None.
SAN FRANCISCO and WALTHAM, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other I&I indications, today announced that members of management, will participate in a fireside chat at the Stifel 2024 Immunology and Inflammation Summit on Wednesday, September 18, 2024 at 12:30 p.m. E.T. / 9:30 a.m. P.T.
A live and archived webcast of the fireside chat and presentation will be available via the News & Events page in the Investors section of the Apogee Therapeutics website.
About Apogee
Apogee Therapeutics is a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other I&I indications. Apogee’s antibody programs are designed to overcome limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. APG777, the company’s most advanced program, is being initially developed for the treatment of AD, which is the largest and one of the least penetrated I&I markets. With four validated targets in its portfolio, Apogee is seeking to achieve best in class efficacy and dosing through monotherapies and combinations of its novel antibodies. Based on a broad pipeline and depth of expertise, the company believes it can deliver value and meaningful benefit to patients underserved by today’s standard of care. For more information, please visit www.apogeetherapeutics.com.
Investor Contact:
Noel Kurdi
VP, Investor Relations
Apogee Therapeutics, Inc.
noel.kurdi@apogeetherapeutics.com
Media Contact:
Dan Budwick
1AB
dan@1abmedia.com
FAQ
When is Apogee Therapeutics (APGE) participating in the Stifel 2024 Immunology and Inflammation Summit?
What therapeutic areas does Apogee Therapeutics (APGE) focus on?
How can investors access Apogee Therapeutics' (APGE) presentation at the Stifel 2024 Summit?
What is Apogee Therapeutics' (APGE) stock exchange and ticker symbol?
